CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 35 enrolled
Drug / intervention
Panobinostatdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00667862
NCT00667862Phase 2Completed
CompareCT.gov

A Phase II, Open Label, Single Arm Study of i.v. Panobinostat (LBH589) in Patients With Metastatic Hormone Refractory Prostate Cancer

Novartis Pharmaceuticals·interventional·Posted Apr 28, 2008·Updated Jun 21, 2021

In Brief

A Phase 2 clinical trial evaluating Panobinostat for Prostate Cancer. Completed, enrolled 35 participants across 5 sites.

Detailed Summary

This Phase II single dose study was designed to characterize the safety, tolerability, and efficacy of intravenous (i.v.) panobinostat as a single-agent treatment in participants with hormone refractory prostate cancer.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsProstate Cancer
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedApr 28, 2008
Enrollment StartMar 18, 2008
Primary CompletionNov 5, 2010
TodayJul 2, 2026
Enrollment to primary: 2.6 yearsPosted 18.2 years ago

Interventions

Panobinostatdrug